CHK1 and CHK2 function as effectors of cell cycle checkpoint arrest following DNA damage. Small molecule inhibitors of CHK proteins are under clinical evaluation in combination with chemotherapeutic agents known to induce DNA damage. We examined whether CHK inhibitors could be effective as single agents in malignant cells with inherent DNA damage because of deregulated expression of the oncogene c-Myc. El-myc lymphoma cells showed a dramatic increase in the extent of DNA damage and DNA damage response (DDR) signalling within 1 h of treatment with CHK1 inhibitors followed by caspase-dependent apoptosis and cell death. In p53 wildtype/ARF null El-myc lymphoma cells, apoptotic cell death was preceded by accumulation of DNA damage and the amount of DNA damage correlated with the extent of cell death. This effect was not observed in normal B cells indicating that DNA damage accumulation following CHK inhibition was specific to El-myc lymphoma cells that exhibit inherent DNA damage because of MYCinduced replication stress. Similar results were obtained with another structurally distinct CHK-inhibitor. El-myc p53 null lymphoma cells were more sensitive to a dual CHK1/CHK2 inhibitor than to a CHK1-specific inhibitor. In all cases, the level of DNA damage following treatment was the most consistent indicator of drug sensitivity. Our results suggest that CHK inhibitors would be beneficial therapeutic agents in MYC-driven cancers. We propose that inhibitors of CHK can act in a synthetically lethal manner in cancers with replication stress as a result of these cancers being reliant on CHK proteins for an effective DDR and cell survival.
Introduction
DNA damage in cells can arise from internal causes such as DNA replication errors or metabolic stresses, and from external sources such as environmental insults. To maintain genomic integrity, cells initiate a DNA damage response (DDR) to enable DNA repair before DNA synthesis and/or mitosis (Kastan, 2008) . The checkpoint kinase proteins CHK1 and CHK2, together with MAPKAP kinase 2 (Xiao et al., 2006) , have a major role in maintaining the genomic integrity by initiating cell cycle arrest integral for an effective DDR.
CHK1 can be activated in response to ultraviolet radiation, replication stress and exposure to DNAdamaging agents. CHK1 is a key component of the DDR and is a central mediator of the S and G2/M checkpoints following DNA damage (Liu et al., 2000) . CHK2 is activated by ataxia telangiectasia mutated (ATM) in response to DNA damage and with other signals activates p53 and also induces the S-phase and G2/M checkpoints (Bartek and Lukas, 2003) . CHK1 has also recently been shown to directly affect DNA repair, thereby confirming its functional role as a central defender of genomic integrity (Enders, 2008; Wilsker et al., 2008; Dai and Grant, 2010) .
Inhibitors of CHK proteins have been developed to enhance response to the DNA-damaging effects of cytotoxic drugs (Janetka et al., 2007; Ashwell and Zabludoff, 2008) . It has been proposed that following DNA damage, cancer cells with p53 mutation, and hence a defective G1 checkpoint, would be reliant on the CHK1 and CHK2 mediated S and G2/M checkpoints for cell cycle arrest. Pre-clinical studies demonstrated that two such inhibitors, the CHK1 selective inhibitor PF-477736 (CHK1 Ki 0.49 nM and CHK2 Ki 47 nM) (Blasina et al., 2008) and the dual CHK1/CHK2 inhibitor AZD7762 Zabludoff et al., 2008) , potentiated the effects of DNA-damaging cytotoxic agents such as gemcitabine, irinotecan and paclitaxel, by inducing tumour cells into mitotic catastrophe and cell death (Janetka et al., 2007; Blasina et al., 2008) . As a result, inhibitors such as these are currently in clinical development in combination with irinotecan or gemcitabine (McArthur et al., in preparation) .
Oncogenes such as Myc and mutant Ras have been shown to induce DNA damage and result in genetic instability (Vafa et al., 2002; Abulaiti et al., 2006) . This oncogene-induced DNA damage can result in apoptosis or senescence during early tumourigenesis (Bartkova et al., 2005 (Bartkova et al., , 2006 Di Micco et al., 2006; . This response needs to be overcome for tumour progression to occur and so defects in the mediators or pathways involved in the DDR are common in established cancer (Bartek et al., 2007; Halazonetis et al., 2008; Negrini et al., 2010) . Most frequently this occurs by loss or mutation of p53 or the DDR pathway (Negrini et al., 2010) . Continued cell survival and proliferation in the presence of intrinsic DNA damage may render such tumour cells reliant on specific checkpoints and repair pathways compared with normal cells, and offers the potential for selective targeting of cancer cells. CHK1 represents one such target as it is a critical mediator for maintaining an effective DDR (Dai and Grant, 2010) .
Given the ability of CHK inhibitors to potentiate exogenous DNA damage inflicted by cytotoxic drugs, we postulated that inhibitors to CHK would also have single-agent activity in tumours with inherent DNA damage resulting from oncogene expression. To address this hypothesis, we utilized the Em-myc model of lymphoma (Adams et al., 1985) that is characterized by oncogene-induced apoptosis and senescence as an initial barrier in the development of lymphoma (Braig et al., 2005) and selection against the ATM-dependent DDR response via disruption of the ARF-Mdm2-p53 pathway as lymphoma progresses (Eischen et al., 1999) . The Em-myc murine model overexpresses MYC in B cells like Burkitt's lymphoma in humans. Here, we show that Em-myc lymphoma cells are sensitive to inhibition of CHK kinases that results in marked enhancement of DNA damage and apoptosis.
Results
The CHK1 inhibitor PF-0477736 shows selective activity for p53 wild-type Em-myc cells as a single agent Cell lines were established from Em-myc lymphoma cell suspensions derived from three individual lymphomas arising in Em-myc Â p53 À/À transgenic mice (labelled p53 null 1, p53 null 2 and p53 null 3) and three individual lymphomas spontaneously arising in Em-myc Â p19 ARFÀ/À transgenic mice (labelled ARF null 1, ARF null 2 and ARF null 3) that retain wild-type p53 (see Supplementary Figure S1A ). The cell lines were treated in vitro with PF-0477736 and dose-dependent effects on cell death were assessed using quantitative flow cytometry. The p53-wild-type ARF-null Em-myc cell lines (average IC 50 of 0.31 mM) were more sensitive to PF-0477736 ( Figure 1a ) compared with the p53-null Em-myc cell lines (average IC 50 of 2.46 mM). The average IC 50 difference (2.15 mM) between the three ARF-null lines and the three p53-null lines by a Welch two sample t-test was significantly different (P ¼ 0.038). Em-myc cell lines treated for 24 h with various doses of PF-0477736 were assessed in clonogenic assays. (Figure 1b and Supplementary Figure S1B ) to determine if the p53-null Em-myc cell lines that survived treatment in short terms assays were able to survive and proliferate or if they underwent death at a later stage. The number of colonies after 1 week (Figure 1b ) paralleled the percentage of surviving cells (Figure 1a ). These data suggest that the differences in sensitivity observed in vitro to PF-0477736 treatment as a single agent, was strongly influenced by the p53 and p19 ARF status of the Em-myc lines.
To determine if similar p53-dependent sensitivity for PF-0477736 was observed in spontaneous Em-myc lymphomas, six additional cell lines (Myc1-Myc6) were assessed. Western blot analyses on the cell lines indicated that Myc1, Myc3, Myc4 and Myc6 cell lines expressed wild-type p53. Myc2 and Myc5 expressed increased levels of p53 with altered mobility on western blot (Supplementary Figure S1A) , coincident with increases in the level of p19ARF expression, suggestive of p53 mutation. During lymphomagenesis in this model, there is a selective pressure for loss of function of either p53 or p19ARF (Eischen et al., 1999; Bertwistle and Sherr, 2007) . Increase in levels of p19ARF is associated with mutant p53 status and loss of p19ARF is associated with functional p53 status. These spontaneous Em-myc cell lines also demonstrated differing sensitivity to PF-0477736 with respect to p53 and p19ARF (Supplementary Figure S1C) . Consistent with previously published results, the p53-wild-type cell lines also displayed increased sensitivity to treatment with conventional cytotoxics such as doxorubicin (Adriamycin), etoposide (VP-16) and g-irradiation (Supplementary Figure S1D -F) (Schmitt et al., 2002) .
PF-0477736 induces apoptosis in Em-myc lymphomas in vivo To evaluate the single-agent activity of PF-0477736 in vivo, the panel of three ARF-null and three p53-null Em-myc lymphoma cell suspensions were transplanted into syngeneic C57BL/6 mice. When the animals developed obvious lymphoma (palpable lymph nodes and elevated white blood cell counts), the transplanted mice were treated with a single dose of 20 mg/kg PF-0477736 (Blasina et al., 2008) . ARF-null Em-myc lymphomas analysed at 6 and 16 h post PF-0477736 treatment displayed a dramatic increase in apoptotic cell death compared with matched vehicle-treated lymphomas ( Figure 2 ). In contrast, p53-null Em-myc lymphomas showed more modest induction of apoptosis. Consistent with these results, PF-0477736 also induced significant decreases in white blood cell counts (Supplementary Figure S2A ) and reduction in spleen weights of mice with ARF-null Em-myc lymphomas (Supplementary Figure S2B (Figure 3a) , Annexin V staining (Figure 3b ), emergence of a sub-G1 fraction by DNA content ( Figure 3c ) and activation of caspase-3 ( Figure 3d ). In contrast, the p53-null Em-myc cell lines displayed only a slight increase in the subG1 population at this time point. As CHK1 inhibition following treatment with DNAdamaging agents had been previously shown to result in death because of mitotic catastrophe, we assessed the proportion of cells expressing phosphorylated-histone H3 (pH3) Single-agent activity of CHK inhibitors PT Ferrao et al (o5%) relative to the sub-G1 fraction (440%) suggests that it was not necessary for the ARF-null Em-myc cells to enter mitosis before undergoing apoptosis. Em-myc cells were also assessed for accumulation of H2AX phosphorylated at S139 (gH2AX) as a marker of DNA damage, in particular double-strand DNA breaks. Cell expressing gH2AX increased with time and progressively 'merged' into the sub-G1 fraction between 2 and 5 h post-treatment ( Figure 3e ). The proportion of cells positive for gH2AX at 2-3 h post-treatment was similar to the proportion of cells displaying apoptosis at 4-5 h and the proportion of dead cells at 16 h posttreatment. Taken together, these data suggest that accumulation of DNA damage in response to PF-0477736 preceded apoptosis in ARF-null Em-myc cells. Interestingly, although the p53-null Em-myc cells accumulated some expression of gH2AX with time, this was not to the same extent as the ARF-null Em-myc cells (Figure 3e ).
Inhibition of CHK1 results in activation of DDR signalling in Em-myc cells
To evaluate the DDR in response to PF-0477736, Em-myc cell line ARF-null 2 were treated with PF-0477736 at a dose of 0.5mM. PF-0477736 that did not result in significant cell death at 2 h post-treatment so that the analyses were reflective of acute signalling changes and not complicated by the effects of cell death. PF-0477736 treatment resulted in phosphorylation of CHK1 on Serine345 and increased with time ( Figure 4a ) as did the levels of gH2AX and pS15-p53. DNA damage is known to result in phosphorylation of p53 at S15 via the ATR-CHK2 pathway. Interestingly, irradiation (5 Gy) also resulted in a similar increase in gH2AX as well as pS15-p53 but did not result in the same level of phosphorylation of CHK1 on S345. In contrast to Em-myc cells, PF-0477736 did not result in an increase in gH2AX or pS15-p53 in normal B-lymphocytes ( Figure 4b ). pS345 CHK was not detected in normal B cells, which may reflect no Single-agent activity of CHK inhibitors PT Ferrao et al or a low level of active CHK1 in these cells that do not display inherent DNA damage and hence would not inherently display an active DDR. A downstream target of CHK1, pY15CDK1 was modulated following PF-0477736 treatment (Figure 4b ). Together these results indicate that inhibition of CHK1 in ARF-null Em-myc cells but not normal B-lymphocytes results in accumulation of DNA damage and activate DDR signalling to p53. The DDR was also assessed in three p53-null Em-myc cell lines. Similar to the ARF-null Em-myc cell lines, PF-0477736 also increased pS345 and pS317 on CHK1 in the p53-null Em-myc cells but did not result in the same levels of increase in gH2AX (Figure 4c ). These data suggest that PF-0477736 induces some accumulation of DNA damage in all Em-myc cell lines but to a much greater extent in the ARF-null Em-myc cells. As oncogene-induced DNA damage can also activate p53, we examined expression of MYC in all cell lines after treatment with PF-0477736. However, there were no significant differences in MYC levels following PF-0477736 treatment suggesting that modulation of MYC in the cells were not directly responsible for the signalling changes observed (Figure 4c ).
PF-0477736 increases DNA damage in Em-myc lymphoma cells
To more thoroughly examine the extent and nature of DNA damage following treatment with PF-0477736, the Em-myc cell lines were further analysed by immunofluorescence for foci of gH2AX. All Em-myc cells had gH2AX foci in the untreated state indicative of constitutive double-strand breaks and inherent DNA damage (Figure 5a ). Following treatment with PF-0477736 for 2 h, there was an increase in the number of gH2AX foci that culminated in a proportion of ARFnull Em-myc cells developing intense staining for gH2AX together with nuclear morphological characteristics of apoptosis. These effects were further characterized by the comet assay (conducted under alkaline conditions) that showed a similar increase in DNA damage with significantly larger comets and higher Olive tail moments following treatment with PF-0477736 (Figure 5b ). This suggested that increased levels of gH2AX were a measure of increased levels of DNA damage in Em-myc cells following PF-0477736 treatment. Consistent with earlier results, ARF-null Em-myc cells had higher levels of DNA damage compared with p53-null Em-myc cells. An increase in the number of mitotic figures with aberrant features was observed in all Em-myc cell lines following PF-0477736 treatment (Figure 5c Single-agent activity of CHK inhibitors PT Ferrao et al marker pH3 indicating accumulation of DNA damage at earlier phases of the cell cycle (Figure 5d , Supplementary Figure S3 and Table S2 ). Together these analyses indicated that inhibition of CHK1 with PF-0477736 led to accumulation of DNA damage, and induction of a DDR independent of inhibition of the G2/M checkpoint. As DNA damage can be associated with caspasedependent apoptotic cell death, we enforced expression of anti-apoptotic protein BCL-2 in each of the ARF-null Em-myc cell lines (Supplementary Figure S4A) that abrogated PF-0477736-induced cell death at 16 h after treatment (Supplementary Figure S4B) . However, consistent with DNA damage still occurring following PF-0477736 treatment, the cells still showed persisting increases in gH2AX 2-6 h post-treatment (Supplementary Figure S4C) . Importantly, treatment of the BCL-2 expressing cells with PF-0477736 still reduced clonogenic survival (Figure 6a , Supplementary Figure S4D ), because of caspase-independent cell death between 24 and 48 h (Figures 6b and c,  Supplementary Figure S4E) , in contrast to caspasedependent cell death of the ARF-null Em-myc parental cell lines within 16 h (Figures 1a and 3d) . Treatment with PF-0477736 induced changes consistent with autophagy (Figures 6d and e) . Simultaneous treatment with chloroquine to inhibit autophagy resulted in increased cell death at the later time point (Supplementary Figure S4F ), suggesting that autophagy was contributing to survival in these cells following treatment with PF-0477736. Taken together these data suggest that ARF-null Em-myc cells are reliant on CHK1 for survival.
Inhibition of CHK1 and CHK2 results in accumulation of DNA damage and cell death in ARF-null and p53-null Em-myc cells Our results indicated reliance on CHK1 in ARF-null Em-myc cells with functional p53 but not in p53-null Emmyc cells. We postulated that during the establishment Single-agent activity of CHK inhibitors PT Ferrao et al of ARF-null Em-myc lymphomas there would be selective pressure to prevent a DDR response activating p53 via CHK2, thus preventing apoptosis because of MYC-driven DNA damage. However, this same selective pressure would not occur in p53-null Em-myc cells already defective in p53 mediated apoptosis. Hence, it was possible that inhibition of both CHK1 and CHK2 would be necessary in p53-null Em-myc cells. Treatment with AZD7762 (a dual CHK1/CHK2 inhibitor) in p53-null Em-myc cells was able to increase the percentage of cell death (Figure 7a ), which was preceded by an increase in the level of DNA damage as shown by increased gH2AX (Figure 7b ). Signalling following AZD7762 treatment in all the ARF-null and p53-null lines (Figure 7b ) indicates the most obvious difference was the level of gH2AX phosphorylation in the p53-null lines following PF-0477736 and AZD7762 (compare Figures 4c and 7b) . Although ARF-null Em-myc cells tended to be more sensitive to AZD7762 than the p53-null Em-myc cells, the average IC50 for the ARF-null Em-myc cell lines (0.52 mM) was not significantly different to the average IC50 for the p53-null Em-myc cell lines (1.69 mM). ARF-null Em-myc cells were overall slightly less sensitive to AZD7762 than PF-0477736 (compare Figures 1a and 7a ), which could be explained by the relative potency of CHK1 inhibition of the two inhibitors and consequent differences in the level of DNA damage accumulated following treatment Single-agent activity of CHK inhibitors PT Ferrao et al (Figure 7c ). In all cases, the level of DNA damage determined by gH2AX was the most consistent indicator of sensitivity to the CHK inhibitors in Em-myc cells, (see Figures 1a, 4c and 7a-c ).
An inhibitor of CDK2 but not the other DDR kinases shows activity on Em-myc cells
We examined sensitivity to several selective inhibitors of other kinases involved in modulating the DDR including CDK2, ATM and DNA-PK. As was the case for PF-0477736 and AZD7762, the ARF-null Em-myc cell lines (average IC 50 1.8 mM) were more sensitive to the selective CDK2 inhibitor PHA533533 (Mercurio et al., 2004; Deans et al., 2006) compared with the p53-null Em-myc cell lines (average IC 50 4.4 mM) (Supplementary Figure S5A) although only at high doses. Selective inhibitors to ATM (KU55933) (Hickson et al., 2004) and DNA-PK (KU57788 or NU7441) (Zhao et al., 2006) resulted in cell death only at high drug doses (43 mM) (Supplementary Figures S5B and  C) . Hence, inhibition of CHK kinases, but not all DDRkinases, was able to result in drug-induced effectual cell death in Em-myc cells.
Discussion
Checkpoint kinase inhibitors are currently in clinical development as combination therapies with DNAdamaging cytotoxic agents. Here, we have demonstrated that checkpoint kinase inhibitors can also have singleagent activity in tumours with inherent DNA damage induced by MYC. Some oncogenes including Myc induce DNA damage principally by the generation of replicative stress (Vafa et al., 2002; Abulaiti et al., 2006) because of direct effects on DNA replication (Dominguez-Sola et al., 2007) . Recently, ATR and CHK1 were shown to suppress a caspase-dependent apoptotic response following DNA replication stress (Myers et al., 2009) . We therefore evaluated the efficacy of CHK1 inhibition in the Em-myc lymphoma model that displays inherent DNA damage and offers the advantage of genetic analysis using well-characterized mouse strains.
Treatment of Em-myc cells with the selective CHK1 inhibitor PF-0477736 induced an increase in the level of DNA damage as assessed by flow cytometry, immunofluorescence, comet assay and western blot analysis. This accumulation of DNA damage following inhibition of CHK1 was not observed in normal B cells suggesting that MYCdriven intrinsic/on-going DNA damage sensitized cells to PF-0477736-induced apoptosis (Reimann et al., 2007) . Recent studies have identified several roles for CHK1 in repair of damaged DNA (Dai and Grant, 2010) and shown that CHK inhibitors sensitize cells to cytotoxics or irradiation by inhibition of homologous recombination DNA repair or Rad51, respectively (Parsels et al., 2009; Morgan et al., 2010) , providing some mechanistic explanations into how inhibition of CHK1 may increase DNA damage in cells harbouring oncogenic stress. Additionally, recent studies that have revealed roles for CHK1 in suppressing apoptosis (Sidi et al., 2008; Myers et al., 2009 ) also providing explanation for apoptosis observed following CHK1 inhibition without preceding/ concurrent G2/M checkpoint inhibition.
TP53 is a central mediator of the DDR and so we chose the Em-myc murine model of lymphoma because of the availability of MYC-driven lymphomas that develop spontaneous defects in the p53/ARF/mdm2 axis (Eischen et al., 1999) . To compare cells with/without functional p53, we used six separate Em-myc lymphoma cell lines derived on either a p53-null or a p19ARF-null (p53 functional) background to overcome the inherent selective pressures for such alterations thereby limiting the possibility of additional alterations. Our results following treatment with PF-0477736 confirmed intrinsic DNA damage in all of these cell lines but showed more selective activity of this inhibitor in the ARF-null Em-myc cells with functional p53. This was contrary to what had been previously reported in relation to combination treatment with CHK inhibitors on solid tumour cell lines that were more effective in cells with mutated p53 (Janetka et al., 2007; Ashwell and Zabludoff, 2008; Blasina et al., 2008; Zabludoff et al., 2008) . Haematopoietic cells are more susceptible to death via apoptosis in a p53 and caspasedependent manner (Lotem and Sachs, 1993) . Interestingly, CHK1 inhibition resulted in only a slight increase in accumulation of gH2AX in p53-null Em-myc cells, suggesting that these cells were perhaps not as reliant on CHK1 for a DDR to maintain genomic integrity. Loss of clonogenic potential in ARF-null Em-myc cells expressing BCL2 because of delayed caspase-independent cell death (despite the induction of early autophagy as a survival mechanism), further supported the effect of PF-0477736 in inducing cell death following accumulation of DNA damage. Therefore, inhibition of CHK1 in p53 competent cells could provide an important strategy to activate p53 and induce cell death in haematopoietic malignancies.
Inhibition of CHK1 and CHK2 by AZD7762 was more effective in p53-null Em-myc cells than selective inhibition of CHK1 by PF-0477736 suggesting that CHK2 is important in maintaining genomic stability in these cells. It is likely that MAPKAP kinase 2 also has a role in the DDR maintaining cell survival of p53-null Em-myc cells (Reinhardt et al., 2007) . Taken together, our data show that the extent of DNA damage following treatment was the most consistent indicator of sensitivity.
Although inhibition of CHK was effective in inducing cell death, inhibition of CDK2 was only effective at high doses and inhibition of ATM or DNA-PK were ineffective, suggesting a critical role for CHK proteins in Em-myc lymphomas. Recent studies have demonstrated that reduction of CHK1 can increase DNA damage and/or lead to reduction in cell viability in U20S cells (Zenvirt et al., 2010) , N-Myc-driven neuroblastoma cells (Cole et al., 2011) and pancreatic carcinoma cells (Giroux et al., 2006) . These data all support CHK1 inhibition as beneficial in the treatment of malignancies with distinct genomic profiles that commonly exhibit high basal replication/cellular stress and inherent DNA damage, including various MYCdriven malignancies. We predict that gH2AX foci levels could be a potentially useful biomarker (Redon et al., 2010) as it is a measure of inherent damage (Lord and Ashworth, 2009) and is required for maintaining genomic stability under replication stress (Chanoux et al., 2009) .
Our results suggest that the genetic background of a tumour may be highly influential in determining the efficacy of treatment with CHK inhibitors. Therefore, stratifying patients based on predictors of sensitivity will be necessary to achieve beneficial clinical outcomes from the use of CHK inhibitor therapeutics.
Materials and methods

Cell culture and transductions
All cell lines were established by in vitro culturing of single cell suspensions from spontaneous lymphomas arising in Em-myc (Myc), Em-myc Â p53 À/À (p53-null) or Em-myc Â p19 ARFÀ/À (ARFnull) transgenic mice, as described previously (Lindemann et al., 2007) . Em-myc vector and Em-myc Bcl-2 expressing cell lines were engineered by retroviral transduction of lymphoma cells with the MSCV IRES green fluorescent protein vector or MSCV IRES green fluorescent protein (Bcl2) respectively, and fluorescenceactivated cell sorting for green fluorescent protein expression using the BD FACSDiva (Becton Dickinson, Franklin Lakes, NJ, USA) as described previously (Lindemann et al., 2007) .
Small molecule inhibitors PF-047736 was provided by Pfizer Oncology, La Jolla, CA, USA. PHA533533 was provided by Pharmacia Corporation (acquired by Pfizer). AZD7762, KU55933 and KU57788 were purchased from SYNthesis Med Chem Pty Ltd, Shanghai, China.
In vitro cell death and apoptosis analysis by flow cytometry Em-myc lymphoma cells (1 Â 10 5 ) were treated with compounds for 16 h in 96-well trays and the cell viability assessed by staining with 1 mg/ml propidium iodide (Sigma Aldrich Co, St Louis, MO, USA) (Newbold et al., 2008) and flow cytometry using the BD LSRII. Data were analysed using FACSExpress. To determine the percentage viability, the data were expressed as a percentage of live cells relative to solventtreated cells. These data were used to calculate a best fit sigmoid dose-response curve using the statistical computing program 'R' (R DCT, 2009). Em-myc cells treated for 5 h were assessed for Annexin V APC (Becton Dickinson), and propidium iodide staining or assessed for DCM (MOMP) using tetramethyl-rhodamine ethyl ester (Invitrogen, Molecular Probes, Eugene, OR, USA) staining as described previously (Newbold et al., 2008) . Cell cycle was analysed by DNA staining using propidium iodide on cells fixed in 95% ethanol at various times following drug treatment (Lindemann et al., 2007) . For dual staining with additional markers, cells were permeabilized (1 M HCl, 0.5% Triton X-100) following ethanol fixation and stained with anti-PH3 or anti-gH2AX followed by Alexa488-conjugated sheep anti-mouse-IgG before propidium iodide staining (as described for BrdU staining) (Deans et al., 2006) .
Colony assays
Em-myc lymphoma cells (5 Â 10 4 ) in 1.5 ml of each well of a 24-well plate were treated with compounds for 24 h. Cells were plated in soft agar assays as described previously (Nguyen et al., 2007) . After 7 days of incubation at 37 1C in a 5% CO 2 humidified incubator, colonies were counted using a dissecting microscope.
In vivo analysis of transplanted mice All procedures conducted were approved by the Peter MacCallum Cancer Centre Animal Ethics Committee. Emmyc lymphoma cells (5 Â 10 5 ) were intravenously injected into individual C57Bl/6 mice of age 6-8 weeks (Lindemann et al., 2007) . Mice were monitored routinely for weight and palpable lymph nodes and other ethical considerations. Mice were treated on days specified by intraperitoneal injection of 20 mg/ kg PF-0477736 in vehicle (49 mg/ml mannitol, 0.05%v/v lactic acid buffer). Lymphomas were fixed in 10% normal buffered formalin, 4 mm sections were cut and stained with haematoxylin and eosin or stained for the TUNEL assay as described previously (Lindemann et al., 2007) . Peripheral white blood cells counts were calculated for whole blood samples by analysis on the Advia 120 Haematology Blood Cell Analyser (Siemens, Healthcare Diagnostics, Deerfield, IL, USA) using the adjusted settings for mice: C57Bl/6. Microscopic analysis (cytology, staining, immunofluorescence) Cells (2.5 Â 10 4 ) cytospun onto microscopy slides were stained with May-Gru¨nwald Giemsa for morphology as described previously (Wall et al., 2008) . Cells were fixed in 10% normal buffered formalin (5 min), stained with antibodies (Supplementary Table S1 ) diluted in Dako diluent (Dako, Carpinteria, CA, USA), washed in phosphate-buffered saline and mounted in ProLong Gold Antifade Reagent containing 4,6-diamidino-2-phenylindole (Invitrogen), for immunofluorescence.
Comet assays
Em-myc (5 Â 10 5 ) lymphoma cells were treated with compounds for 2 h and the cells analysed using the CometAssay kit (Trevigen, Gaithersburg, MD, USA) according to the manufacturer's instructions (Deans et al., 2006) . Cells were viewed using a BX-51 microscope (Olympus, Tokyo, Japan) and images obtained using a SPOT RT3 slide camera. The relative length and intensity of ethidium bromide-stained DNA 'tails' to 'heads' is proportional to the amount of DNA damage present in the individual nuclei. The Olive tail moment (tail length Â (tail fluorescence/ (head þ tail fluorescence))) was quantified utilizing Metamorph Microscopy Automation and Image Analysis Software (Ottawa, Ontario, Canada).
Ultrastructural analysis of cells by transmission electron microscope Drug-treated cells were fixed in 2% paraformaldehyde/2.5% glutaraldehyde in 0.08 M Sorensen's phosphate-buffered saline, post-fixed with 2% osmium tetroxide in phosphate-buffered saline, followed by dehydration through alcohol, acetone rinses and embedding in Spurrs resin (Spurr, 1969; Nguyen et al., 2007) . In all, 80 nm sections were cut with a diamond knife (Diatome, Biel, Switzerland) in an Ultracut-S ultramicrotome (Leica, Solms, Germany) and contrasted with uranyl acetate and lead citrate. Images were captured with a Megaview II cooled CCD camera (Olympus) in a JEOL 1011 transmission electron microscope.
Western blot analysis
Whole-cell lysates were prepared by addition of buffer and sonication; separated by sodium dodecyl sulphate/10-15% polyacrylamide gel electrophoresis and analysed by estern blotting as described previously (Deans et al., 2006) using antibodies listed in Supplementary Table S1 .
Statistical analysis
To obtain IC 50 values, the dose-response data were fitted to a three-parameter log-logistic (LL.3) function using the 'drm' library in the R statistical computing program (R DCT, 2009) fixing the top of the curve to 100%. A two sample Welch t-test was used to test for a difference in the mean IC 50 values. A t-test using GraphPad Prism (GraphPad Software Inc., La Jolla, CA, USA) was used for other analyses.
